Toxic shock syndrome (TSS) is a severe, multi-system illness triggered by bacterial superantigens, primarily from Staphylococcus aureus and Streptococcus pyogenes. Clinical presentation often involves sudden high fever, hypotension, and a characteristic peeling rash, which can rapidly progress to organ failure or death. While historically linked to high-absorbency tampons, current research highlights risks from surgical wounds, skin infections, and a recent spike in invasive streptococcal cases globally. To combat this threat, scientists are evaluating MS473, a human antibody fragment that demonstrated a 100% survival rate in animal models by neutralising toxins. Other preventative efforts include the development of recombinant vaccines and public health monitoring of antibiotic-resistant pathogens. Managing the disease effectively requires early diagnosis and aggressive treatment to prevent the catastrophic cytokine stormassociated with the condition.